{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Kemp KL"],"funding":["The University of Queensland Graduate School Research Training Program (RTP) Scholarship","Morris Animal Foundation","Destination Australia Scholarship"],"pagination":["1177-1184"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10937495"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["38(2)"],"pubmed_abstract":["<h4>Background</h4>Phenylbutazone is often prescribed to manage pain caused by hyperinsulinemia-associated laminitis, but in diabetic people nonsteroidal anti-inflammatory drugs increase insulin secretion and pancreatic activity.<h4>Hypothesis/objectives</h4>Investigate the effect of phenylbutazone administration on insulin secretion in horses. It was hypothesized that phenylbutazone will increase insulin secretion in horses with insulin dysregulation (ID).<h4>Animals</h4>Sixteen light breed horses, including 7 with ID.<h4>Methods</h4>Randomized cross-over study design. Horses underwent an oral glucose test (OGT) after 9 days of treatment with phenylbutazone (4.4 mg/kg IV q24h) or placebo (5 mL 0.9% saline). After a 10-day washout period, horses received the alternative treatment, and a second OGT was performed. Insulin and glucose responses were compared between groups (ID or controls) and treatments using paired t test and analyses of variance with P < .05 considered significant.<h4>Results</h4>In horses with ID, phenylbutazone treatment significantly decreased glucose concentration (P = .02), glucose area under the curve (2429 ± 501.5 vs 2847 ± 486.1 mmol/L × min, P = .02), insulin concentration (P = .03) and insulin area under the curve (17 710 ± 6676 vs 22 930 ± 8788 μIU/mL × min, P = .03) in response to an OGT. No significant effect was detected in control horses.<h4>Conclusion and clinical importance</h4>Phenylbutazone administration in horses with ID decreases glucose and insulin concentrations in response to an OGT warranting further investigation of a therapeutic potential of phenylbutazone in the management of hyperinsulinemia-associated laminitis beyond analgesia."],"journal":["Journal of veterinary internal medicine"],"pubmed_title":["Effect of phenylbutazone on insulin secretion in horses with insulin dysregulation."],"pmcid":["PMC10937495"],"funding_grant_id":["D19‐EQ‐302","D19-EQ-302"],"pubmed_authors":["Kemp KL","Skinner JE","Bertin FR"],"additional_accession":[]},"is_claimable":false,"name":"Effect of phenylbutazone on insulin secretion in horses with insulin dysregulation.","description":"<h4>Background</h4>Phenylbutazone is often prescribed to manage pain caused by hyperinsulinemia-associated laminitis, but in diabetic people nonsteroidal anti-inflammatory drugs increase insulin secretion and pancreatic activity.<h4>Hypothesis/objectives</h4>Investigate the effect of phenylbutazone administration on insulin secretion in horses. It was hypothesized that phenylbutazone will increase insulin secretion in horses with insulin dysregulation (ID).<h4>Animals</h4>Sixteen light breed horses, including 7 with ID.<h4>Methods</h4>Randomized cross-over study design. Horses underwent an oral glucose test (OGT) after 9 days of treatment with phenylbutazone (4.4 mg/kg IV q24h) or placebo (5 mL 0.9% saline). After a 10-day washout period, horses received the alternative treatment, and a second OGT was performed. Insulin and glucose responses were compared between groups (ID or controls) and treatments using paired t test and analyses of variance with P < .05 considered significant.<h4>Results</h4>In horses with ID, phenylbutazone treatment significantly decreased glucose concentration (P = .02), glucose area under the curve (2429 ± 501.5 vs 2847 ± 486.1 mmol/L × min, P = .02), insulin concentration (P = .03) and insulin area under the curve (17 710 ± 6676 vs 22 930 ± 8788 μIU/mL × min, P = .03) in response to an OGT. No significant effect was detected in control horses.<h4>Conclusion and clinical importance</h4>Phenylbutazone administration in horses with ID decreases glucose and insulin concentrations in response to an OGT warranting further investigation of a therapeutic potential of phenylbutazone in the management of hyperinsulinemia-associated laminitis beyond analgesia.","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Mar-Apr","modification":"2026-06-24T03:08:32.473Z","creation":"2026-06-24T03:06:03.41Z"},"accession":"S-EPMC10937495","cross_references":{"pubmed":["38363029"],"doi":["10.1111/jvim.17013"]}}